Enhanced anticancer activity of DM1-loaded star-shaped folate-core PLA-TPGS nanoparticles

Nanoscale Research Letters

Volumn 9, Issue 1, 2014, Pages

  Tang, Xiaolong ^a,b   Liang, Yong ^c   Zhu, Yongqiang ^d   Cai, Shiyu ^a   Sun, Leilei ^e   Chen, Tianyi ^a  

^a ANHUI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN UNIVERSITY   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Drug delivery; Emtansine (DM1); Targeting nanoparticles

Indexed keywords

CELLS; CONTROLLED DRUG DELIVERY; CYTOLOGY; DRUG DELIVERY; DRUG PRODUCTS; MAMMALS; NANOPARTICLES; STARS; TUMORS;

ANTI-TUMOR ACTIVITIES; ANTICANCER ACTIVITIES; CRITICAL CHALLENGES; DRUG ENCAPSULATION EFFICIENCY; EMTANSINE (DM1); PHOSPHATE-BUFFERED SALINES; POTENTIAL FORMULATIONS; TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATES;

TARGETED DRUG DELIVERY;

MUS;

EID: 84919933115     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-9-563     Document Type: Article

References (40)

1. Lv S, Tang Z, Li M, Lin J, Song W, Liu H, Huang Y, Zhang Y, Chen X: Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.Biomaterials 2014,35(23):6118–6129. 10.1016/j.biomaterials.2014.04.034
2. Wang M, Zhang Y, Sun B, Sun Y, Gong X, Wu Y, Zhang X, Kong W, Chen Y: Permeability of exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine.Biol Pharm Bull 2014,37(5):740–747. 10.1248/bpb.b13-00591
3. Maeda H, Sawa T, Konno T: Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.J Control Release 2001,74(1–3):47–61.
4. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC: Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.Cancer Res 2013,73(8):2412–2417. 10.1158/0008-5472.CAN-12-4561
5. Tan GR, Feng SS, Leong DT: The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles.Biomaterials 2014,35(9):3044–3051. 10.1016/j.biomaterials.2013.12.033
6. Zhao J, Feng SS: Effects of PEG tethering chain length of vitamin E TPGS with a Herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs.Biomaterials 2014,35(10):3340–3347. 10.1016/j.biomaterials.2014.01.003
7. Sendur MA, Aksoy S, Ozdemir Y, Zengin N, Altundag K: Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab?J BUON 2013,18(3):801.
8. Bighin C, Pronzato P, Del Mastro L: Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients.Future Oncol 2013,9(7):955–957. 10.2217/fon.13.74
9. Gradishar WJ: Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.Ann Oncol 2013,24(10):2492–2500. 10.1093/annonc/mdt217
10. Poon KA, Flagella K, Beyer J, Tibbitts J, Kaur S, Saad O, Yi JH, Girish S, Dybdal N, Reynolds T: Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.Toxicol Appl Pharmacol 2013,273(2):298–313. 10.1016/j.taap.2013.09.003
11. Kümler I, Tuxen MK, Nielsen DL: A systematic review of dual targeting in HER2-positive breast cancer.Cancer Treat Rev 2014,40(2):259–270. 10.1016/j.ctrv.2013.09.002
12. Venghateri JB, Gupta TK, Verma PJ, Kunwar A, Panda D: Ansamitocin P3 depolymerizes microtubules and induces apoptosis by binding to tubulin at the vinblastine site.PLoS One 2013,8(10):e75182. 10.1371/journal.pone.0075182
13. Lopus M, Yenjerla M, Wilson L: Microtubule dynamics. In Encyclopedia of Chemical Biology. 3. Edited by: Begley TP. New Jersey: John Wiley & Sons; 2009:153–160.
14. Haddley K: Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.Drugs Today (Barc) 2013,49(11):701–715. 10.1358/dot.2013.49.11.2020937
15. Thery JC, Spano JP, Azria D, Raymond E, Penault LF: Resistance to human epidermal growth factor receptor type 2-targeted therapies.Eur J Cancer 2014,50(5):892–901. 10.1016/j.ejca.2014.01.003
16. Ye P, Zhang W, Yang T, Lu Y, Lu M, Gai Y, Ma X, Xiang G: Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting.Int J Nanomedicine 2014, 9:2167–2178.
17. Hu Y, Ma B, Zhang Y, Wang M: Small molecule-folic acid modification on nanopatterned PDMS and investigation on its surface property.Biomed Microdevices 2014,16(3):487–497. 10.1007/s10544-014-9851-7
18. Leamon CP, Vlahov IR, Reddy JA, Vetzel M, Santhapuram HK, You F, Bloomfield A, Dorton R, Nelson M, Kleindl P, Vaughn JF, Westrick E: Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.Bioconjug Chem 2014,25(3):560–568. 10.1021/bc400441s
19. Shi J, Wang L, Gao J, Liu Y, Zhang J, Ma R, Liu R, Zhang Z: A fullerene-based multi-functional nanoplatform for cancer theranostic applications.Biomaterials 2014,35(22):5771–5784. 10.1016/j.biomaterials.2014.03.071
20. Zheng M, Zhao P, Luo Z, Gong P, Zheng C, Zhang P, Yue C, Gao D, Ma Y, Cai L: Robust ICG theranostic nanoparticles for folate targeted cancer imaging and highly effective photothermal therapy.ACS Appl Mater Interfaces 2014,6(9):6709–6716. 10.1021/am5004393
21. Torchilin V: Tumor delivery of macromolecular drugs based on the EPR effect.Adv Drug Deliv Rev 2011,63(3):131–135. 10.1016/j.addr.2010.03.011
22. Maeda H: Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.Bioconjug Chem 2010,21(5):797–802. 10.1021/bc100070g
23. Zhu Q, Feng C, Liao W, Zhang Y, Tang S: Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model.Cancer Cell Int 2013,13(1):65. 10.1186/1475-2867-13-65
24. Wang R, Hu X, Wu S, Xiao H, Cai H, Xie Z, Huang Y, Jing X: Biological characterization of folate-decorated biodegradable polymer-platinum(II) complex micelles.Mol Pharm 2012,9(11):3200–3208. 10.1021/mp3002914
25. Bartsch R, Berghoff AS, Preusser M: Breast cancer brain metastases responding to primary systemic therapy with T-DM1.J Neurooncol 2014,116(1):205–206. 10.1007/s11060-013-1257-5
26. Park JH, Lee JY, Termsarasab U, Yoon IS, Ko SH, Shim JS, Cho HJ, Kim DD: Development of poly(lactic-co-glycolic) acid nanoparticles-embedded hyaluronic acid-ceramide-based nanostructure for tumor-targeted drug delivery.Int J Pharm 2014,473(1–2):426–433.
27. Zeng X, Tao W, Mei L, Huang L, Tan C, Feng SS: Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer.Biomaterials 2013,34(25):6058–6067. 10.1016/j.biomaterials.2013.04.052
28. Zhang Y, Yang H, Barnie PA, Yang P, Su Z, Chen J, Jiao Z, Lu L, Wang S, Xu H: The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer.Int J Med Sci 2014,11(6):608–613. 10.7150/ijms.8428
29. Niu G, Carter WB: Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.Cancer Res 2007,67(4):1487–1493. 10.1158/0008-5472.CAN-06-3155
30. Tang X, Cai S, Zhang R, Liu P, Chen H, Zheng Y, Sun L: Paclitaxel-loaded nanoparticles of star-shaped cholic acid-core PLA-TPGS copolymer for breast cancer treatment.Nanoscale Res Lett 2013,8(1):420. 10.1186/1556-276X-8-420
31. Abdelmontalab FY, Fadl EI, Abushama H, Kreskowski K, Liehr T: Molecular cytogenetic study of the NF2 gene deletion in meningioma in Sudanese patients.Balkan J Med Genet 2013,16(2):29–32.
32. Merkhofer EC, Cogswell P, Baldwin AS: Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha.Oncogene 2010,29(8):1238–1248. 10.1038/onc.2009.410
33. YSlamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med 2001,344(11):783–792. 10.1056/NEJM200103153441101
34. Khoshgard K, Hashemi B, Arbabi A, Rasaee MJ, Soleimani M: Radiosensitization effect of folate-conjugated gold nanoparticles on HeLa cancer cells under orthovoltage superficial radiotherapy techniques.Phys Med Biol 2014,59(9):2249–2263. 10.1088/0031-9155/59/9/2249
35. Li L, Yang Q, Zhou Z, Zhong J, Huang Y: Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.Biomaterials 2014,35(19):5171–5187. 10.1016/j.biomaterials.2014.03.027
36. Tavassolian F, Kamalinia G, Rouhani H, Amini M, Ostad SN, Khoshayand MR, Atyabi F, Tehrani MR, Dinarvand R: Targeted poly (l-γ-glutamyl glutamine) nanoparticles of docetaxel against folate over-expressed breast cancer cells.Int J Pharm 2014,467(1–2):123–138.
37. Vijayakumar MR, Muthu MS, Singh S: Copolymers of poly(lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy.Expert Opin Drug Deliv 2013,10(4):529–543. 10.1517/17425247.2013.758632
38. Wu SR, Cheng TS, Chen WC, Shyu HY, Ko CJ, Huang HP, Teng CH, Lin CH, Johnson MD, Lin CY, Lee MS: Matriptase is involved in ErbB-2-induced prostate cancer cell invasion.Am J Pathol 2010,177(6):3145–3158. 10.2353/ajpath.2010.100228
39. Zheng J, Wang H, Yao J, Zou X: More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.Pharmazie 2014,69(1):38–42.
40. Barok M, Tanner M, Köninki K, Isola J: Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.Breast Cancer Res 2011,13(2):R46. 10.1186/bcr2868